$131 Million is the total value of OUP Management Co., LLC's 16 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was 0.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
Sell | ionQ, Inc. | $29,597,000 | -57.3% | 2,319,519 | -44.1% | 22.54% | -27.8% | |
CNTA | Buy | Centessa Pharmaceuticals plcsponsored ads | $26,350,000 | -0.1% | 2,937,615 | +25.4% | 20.06% | +68.8% |
PMVP | PMV Pharmaceuticals, Inc. | $20,596,000 | -9.9% | 989,232 | 0.0% | 15.68% | +52.3% | |
AVTE | Aerovate Therapeutics Inc. | $11,067,000 | +55.5% | 603,762 | 0.0% | 8.43% | +162.7% | |
DICE Therapeutics Inc. | $10,267,000 | -24.4% | 536,693 | 0.0% | 7.82% | +27.7% | ||
CYT | Cyteir Therapeutics, Inc. | $9,329,000 | -66.8% | 2,474,572 | 0.0% | 7.10% | -44.0% | |
Evolv Technologies Holdings, Inc. | $4,825,000 | -40.6% | 1,820,866 | 0.0% | 3.67% | +0.4% | ||
eFFECTOR Therapeutics, Inc. | $4,113,000 | -51.6% | 1,025,697 | 0.0% | 3.13% | -18.2% | ||
DTIL | Precision BioSciences, Inc. | $3,462,000 | -58.4% | 1,123,913 | 0.0% | 2.64% | -29.7% | |
LABP | Landos Biopharma, Inc. | $2,696,000 | -69.3% | 1,827,478 | 0.0% | 2.05% | -48.1% | |
VOR | Vor Biopharma Inc. | $2,263,000 | -48.0% | 374,714 | 0.0% | 1.72% | -12.2% | |
SPRO | Spero Therapeutics, Inc. | $2,167,000 | -45.7% | 249,070 | 0.0% | 1.65% | -8.2% | |
GRPH | Graphite Bio | $2,072,000 | -59.0% | 406,308 | 0.0% | 1.58% | -30.7% | |
Sell | Sera Prognostics, Inc. | $1,279,000 | -71.0% | 337,505 | -47.4% | 0.97% | -51.0% | |
SELB | Selecta Biosciences, Inc. | $1,061,000 | -62.3% | 862,543 | 0.0% | 0.81% | -36.2% | |
FIXX | Homology Medicines, Inc. | $195,000 | -16.3% | 64,000 | 0.0% | 0.15% | +41.0% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-05-04
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
Centessa Pharmaceuticals plc | 8 | Q3 2023 | 42.7% |
Aerovate Therapeutics Inc. | 8 | Q3 2023 | 28.9% |
PMV Pharmaceuticals, Inc. | 8 | Q3 2023 | 19.4% |
Cyteir Therapeutics, Inc. | 8 | Q3 2023 | 15.7% |
Vor Biopharma Inc. | 8 | Q3 2023 | 4.1% |
Precision BioSciences, Inc. | 8 | Q3 2023 | 3.7% |
Graphite Bio | 8 | Q3 2023 | 2.3% |
eFFECTOR Therapeutics, Inc. | 8 | Q3 2023 | 3.8% |
Selecta Biosciences, Inc. | 8 | Q3 2023 | 2.4% |
Spero Therapeutics, Inc. | 8 | Q3 2023 | 1.8% |
View OUP Management Co., LLC's complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2023-11-09 |
13F-HR | 2023-08-07 |
13F-HR | 2023-04-24 |
13F-HR | 2023-02-02 |
13F-HR | 2022-11-01 |
13F-HR | 2022-07-19 |
13F-HR | 2022-05-04 |
13F-HR | 2022-02-03 |
View OUP Management Co., LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.